compounded semaglutide glp-1 injections FDA alerts health care providers, compounders and patients of dosing errors associated with injectable products Compounded Semaglutide - HelloWellness

Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)

Diabetes Care 2022;45:S144S174

Some of these drugs are now also approved to reduce the risk of heart attacks , strokes, and heart-related deaths in certain populations

DESCRIPTION TABLE OF CONTENTS METHODOLOGY DOWNLOAD PDF GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033 USD 170.75 BN MARKET SIZE, 2033 OVERVIEW Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period